A case for water in the treatment of polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 6, 2009, Pages 1140-1150

  Torres, Vicente E ^a   Bankir, Lise ^b   Grantham, Jared J ^c  

^a Mayo Clinic College of Medicine   (United States)

^b INSERM   (France)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CYCLIC AMP; DIURETIC AGENT; MOZAVAPTAN; SEROTONIN UPTAKE INHIBITOR; TOLVAPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST; WATER;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEHYDRATION; DIURESIS; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HORMONE RELEASE; HUMAN; HYPONATREMIA; KIDNEY CONCENTRATING CAPACITY; KIDNEY CYST; KIDNEY HYPERTROPHY; KIDNEY POLYCYSTIC DISEASE; MAGNOCELLULAR NUCLEUS; MICTURITION; NEPHRONOPHTHISIS; NONHUMAN; PLASMA OSMOLALITY; REVIEW; SUPRAOPTIC NUCLEUS; URINE OSMOLALITY; URINE VOLUME; WATER ABSORPTION; WATER DEPRIVATION; ANIMAL; DRINKING; ELECTROLYTE BALANCE; FLUID THERAPY; METABOLISM;

ANIMALS; ARGININE VASOPRESSIN; DRINKING; FLUID THERAPY; HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; WATER; WATER-ELECTROLYTE BALANCE;

EID: 69249235445     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00790209     Document Type: Review

References (88)

1. Grantham JJ: Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach. Kidney Int 64: 1157-1162, 2003
2. Gattone VH, Maser RL, Tian C, Rosenberg JM, Branden MG: Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Develop Gen 24: 309-318, 1999
3. Gattone VH, Wang X, Harris PC, Torres VE: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nature Med 9: 1323-1326, 2003
4. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nature Med 10: 363-364, 2004
5. Torres VE: Role of vasopressin antagonists. Clin J Am Soc Nephrol 3: 1212-1218, 2008
6. Parks JH, Goldfischer ER, Coe FL: Changes in urine volume accomplished by physicians treating nephrolithiasis. J Urol 169: 863-866, 2003
7. Bankir L, Daudon M: Recurrent (as opposed to non-recurrent) stone formers failed to increase urine volume significantly over a 3-y period in spite of recommendations to drink more, and still showed a higher Tiselius index in morning urine. J Am Soc Nephrol 19: 294A, 2008
8. Grantham JJ: Therapy for polycystic kidney disease? It's water stupid! J Am Soc Nephrol 19: 1-7, 2008
9. Mangoo-Karim R, Uchic M, Lechene C, Grantham JJ: Renal epithelial cyst formation and enlargement in vitro: Dependence on cAMP. Proc Natl Acad Sci U S A 86: 6007-6011, 1989
10. Hanaoka K, Guggino W: cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 11: 1179-1187, 2000
11. Yamaguchi T, Pelling J, Ramaswamy N, Eppler J, Wallace D, Nagao S, Rome L, Sullivan L, Grantham J: cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471, 2000
12. Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM, JJ, G: Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964-973, 2004
13. Wang X, Gattone V, 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005
14. Nagao S, Nishii K, Katsuyama M, Kurahashi H, Marunouchi T, Takahashi H, Wallace DP: Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17: 2220-2227, 2006
15. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE: Vasopressin directly regulates cyst growth in the PCK rat. J Am Soc Nephrol 19: 102-108, 2008
16. Wallace DP, Reif G, Hedge AM, Thrasher JB, Pietrow P: Adrenergic regulation of salt and fluid secretion in human medullary collecting duct cells. Am J Physiol Renal Physiol 287: F639-F648, 2004
17. Putnam WC, Swenson SM, Reif GA, Wallace DP, Helmkamp GM, Jr., Grantham JJ: Identification of a forskolin-like molecule in human renal cysts. J Am Soc Nephrol 18: 934-943, 2007
18. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V: Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 219: 399-405, 1986
19. Michalski A, Grzeszczak W: [The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]. Pol Arch Med Wewn 96: 329-343, 1996
20. Konstam MA, Gheorghiade M, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297: 1319-1331, 2007
21. Gheorghiade M, Konstam MA, Burnett JC, Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 297: 1332-1343, 2007
22. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006
23. Dunn FL, Brennan TJ, Nelson AE, Robertson GL: The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 52: 3212-3219, 1973
24. Robertson GL, Berl, T: Pathophysiology of water metabolism. In: The Kidney. [6th Ed.] edited by M, B. B., Philadelphia, W B Saunders Company, 2000, pp 866-924
25. Robertson GL: Abnormalities of thirst regulation. Kidney Int 25: 460-469, 1984
26. Schrier RW: Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone. Am J Med 119: S47-S53, 2006
27. Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P: Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol 259: R53-R60, 1990
28. Morgenthaler NG, Struck J, Jochberger S, Dunser MW: Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 19: 43-49, 2008
29. Agre, P: Homer W: Smith award lecture. Aquaporin water channels in kidney. J Am Soc Nephrol 11: 764-777, 2000
30. Verkman AS: Roles of aquaporins in kidney revealed by transgenic mice. Semin Nephrol 26: 200-208, 2006
31. Yang B, Bankir L: Urea and urine concentrating ability: New insights from studies in mice. Am J Physiol Renal Physiol 288: F881-F896, 2005
32. Fenton RA, Smith CP, Knepper MA: Role of collecting duct urea transporters in the kidney-Insights from mouse models. J Membr Biol 212: 119-131, 2006
33. Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N: Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension 38: 1143-1149, 2001
34. Schafer JA: Abnormal regulation of ENaC: Syndromes of salt retention and salt wasting by the collecting duct. Am J Physiol Renal Physiol 283: F221-F235, 2002
35. Drummer C, Gerzer R, Heer M, Molz B, Bie P, Schlossberger M, Stadaeger C, Rocker L, Strollo F, Heyduck B, Bauer K, Warberg J, Baisch F, Christensen NJ, Konig A, Norsk P: Effects of an acute saline infusion on fluid and electrolyte metabolism in humans. Am J Physiol 262: F744-F754, 1992
36. Perucca J, Bouby N, Valeix P, Bankir L: Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 292: R700-R705, 2007
37. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372-390, 2001
38. Berl T: Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 19: 1076-1078, 2008
39. Bankir L, Perucca J, Weinberger MH: Ethnic differences in urine concentration: Possible relationship to blood pressure. Clin J Am Soc Nephrol 2: 304-312, 2007
40. Perucca J, Bouby N, Valeix P, Jungers P, Bankir L: [Difference in urine concentration according to gender and ethnicity: Possible involvement in the different susceptibility to various renal and cardiovascular diseases]. Nephrol Ther 4: 160-172, 2008
41. Bricker NS, Dewey RR, Lubowitz H, Stokes J, Kirkensgaard T: Observations on the concentrating and diluting mechanisms of the diseased kidney. J Clin Invest 38: 516-523, 1959
42. Hayslett JP: Functional adaptation to reduction in renal mass. Physiol Rev 59: 137-164, 1979
43. Tannen RL, Regal EM, Dunn MJ, Schrier RW: Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 280: 1135-1141, 1969
44. Chapman A, Guay-Woodford L, JJ, G, Torres V, Bae K, Baumgarten D, Kenney P, King B, Glockner J, Wetzel L, Brummer M, O'Neill C, Robbin M, Bennett W, Klahr S, Hirschman G, Kimmel P, Thompson P, Miller J: Renal structure in early autosomal dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) Cohort. Kidney Int 64: 1035-1045, 2003
45. Gabow P, Kaehny W, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW: The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 35: 675-680, 1989
46. Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, Gabow P: Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 36: 53-57, 2000
47. Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP: Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2: 112-120, 2007
48. Dalgaard OZ: Bilateral polycystic disease of the kidneys: A follow-up of 284 patients and their families. Dan Med Bull 4: 128-133, 1957
49. D'Angelo A, Mioni G, Ossi E, Lupo A, Valvo E, Maschio G: Alterations in renal tubular sodium and water transport in polycystic kidney disease. Clin Nephrol 3: 99-105, 1975
50. Martinez-Maldonado M, Yium JJ, Eknoyan G, Suki WN: Adult polycystic kidney disease: Studies of the defect in urine concentration. Kidney Int 2: 107-113, 1972
51. Nadvornikova H, Schuck O, Prat V, Merta M: [Concentrating ability of the kidneys in patients with polycystic kidneys during a stage of normal values of glomerular filtration]. Vnitr Lek 31: 105-112, 1985
52. Preuss H, Geoly K, Johnson M, Chester A, Kliger A, Schreiner G: Tubular function in adult polycystic kidney disease. Nephron 24: 198-204, 1979
53. Fick G, Duley I, AM, J, Strain J, Manco-Johnson M, Gabow P: The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4: 1654-1660, 1994
54. Kaariainen H, Koskimies O, Norio R: Dominant and recessive polycystic kidney disease in children: Evaluation of clinical features and laboratory data. Pediatr Nephrol 2: 296-302, 1988
55. Seeman T, Dusek J, Vondrak K, Blahova K, Simkova E, Kreisinger J, Dvorak P, Kyncl M, Hribal Z, Janda J: Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53: 629-634, 2004
56. Ahrabi AK, Terryn S, Valenti G, Caron N, Serradeil-Le Gal C, Raufaste D, Nielsen S, Horie S, Verbavatz JM, Devuyst O: PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 18: 1740-1753, 2007
57. Carone FA, Ozono S, Samma S, Kanwar YS, Oyasu R: Renal functional changes in experimental cystic disease are tubular in origin. Kidney Int 33: 8-13, 1988
58. Safouh M, Crocker JF, Vernier RL: Experimental cystic disease of the kidney. Sequential, functional, and morphologic studies. Lab Invest 23: 392-400, 1970
59. Hayashi M, Yamaji Y, Monkawa T, Yoshida T, Tsuganezawa H, Sasamura H, Kitajima W, Sasaki S, Ishibashi K, Maurmo F, Saruta T: Expression and localization of the water channels in human autosomal dominant polycystic kidney disease. Nephron 75: 321-326, 1997
60. Pabico RC, McKenna BA, Freeman RB: Renal tubular dysfunction in patients with cystic disease of the kidneys. Urology 51: 156-160, 1998
61. Valtin H: "Drink at least eight glasses of water a day." Really? Is there scientific evidence for "8 x 8"? Am J Physiol Regul Integr Comp Physiol 283: R993-1004, 2002
62. Negoianu D, Goldfarb S: Just add water. J Am Soc Nephrol 19: 1041-1043, 2008
63. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359: 1477-1485, 2008
64. Liu BA, Mittmann N, Knowles SR, Shear NH: Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. CMAJ 155: 519-527, 1996
65. Movig KL, Leufkens HG, Lenderink AW, van den Akker VG, Hodiamont PP, Goldschmidt HM, Egberts AC: Association between antidepressant drug use and hyponatraemia: A case-control study. Br J Clin Pharmacol 53: 363-369, 2002
66. Hebert LA, Greene T, Levey A, Falkenhain ME, Klahr S: High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 41: 962-971, 2003
67. Clark BA, Shannon RP, Rosa RM, Epstein FH: Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 5: 1106-1111, 1994 68. Starklint J, Bech JN, Nyvad O, Jensen P, Pedersen EB: Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure. Scand J Clin Lab Invest 66: 55-66, 2006
68. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L: Diabetes-induced albuminuria: Role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 18: 1755-1763, 2003
69. Bouby N, Bachmann S, Bichet D, Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258: F973-F979, 1990
70. Bouby N, Hassler C, Bankir L: Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats. Life Sci 65: 991-1004, 1999
71. Okada H, Suzuki H, Kanno Y, Saruta T: Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 72: 667-672, 1996
72. Sugiura T, Yamauchi A, Kitamura H, Matsuoka Y, Horio M, Imai E, Hori M: High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta. Kidney Int 55: 1800-1810, 1999
73. Torres VE, JJ, G, Chapman N, Guay-Woodford L, Bae K, Bennett W, Meyers KE, Lin YT, Bost JE, CRISP: Predictors of disease progression in autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 19: 126A, 2008
74. van Lieburg AF, Knoers NV, Monnens LA: Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 10: 1958-1964, 1999
75. Spigt MG, Knottnerus JA, Westerterp KR, Olde Rikkert MG, Schayck CP: The effects of 6 months of increased water intake on blood sodium, glomerular filtration rate, blood pressure, and quality of life in elderly (aged 55-75) men. J Am Geriatr Soc 54: 438-443, 2006
76. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ: The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 13: 2723-2729, 2002
77. Gill TP, Rangan AM, Webb KL: The weight of evidence suggests that soft drinks are a major issue in childhood and adolescent obesity. Med J Aust 184: 263-264, 2006
78. Gattone VH, Sinders, R: Kidney cystic disease is exacerbated by dichloroacetate in male PCK rats. J Am Soc Nephrol 19: 130A, 1980
79. Doull, J: Fluoride in Drinking Water. Washington DC, The National Academies Press, 2006
80. McCormack M, Dessureault J, Guitard M: The urine specific gravity dipstick: A useful tool to increase fluid intake in stone forming patients. J Urol 146: 1475-1477, 1991
81. Araki S: Effects of urinary volume on urinary concentrations of lead, delta-aminolaevulinic acid, coproporphyrin, creatinine, and total solutes. Br J Ind Med 37: 50-54, 1980
82. Gowans EM, Fraser CG: Biological variation in analyte concentrations in urine of apparently healthy men and women. Clin Chem 33: 847-850, 1987
83. Ricos C, Jimenez CV, Hernandez A, Simon M, Perich C, Alvarez V, Minchinela J, Macia M: Biological variation in urine samples used for analyte measurements. Clin Chem 40: 472-477, 1994
84. Shephard MD, Penberthy LA, Fraser CG: Short- and longterm biological variation in analytes in urine of apparently healthy individuals. Clin Chem 27: 569-573, 1981
85. Curhan GC, Taylor EN: 24-h uric acid excretion and the risk of kidney stones. Kidney Int 73: 489-496, 2008
86. Anastasio P, Cirillo M, Spitali L, Frangiosa A, Pollastro RM, De Santo NG: Level of hydration and renal function in healthy humans. Kidney Int 60: 748-756, 2001
87. Curhan GC, Willett WC, Speizer FE, Stampfer MJ: Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 59: 2290-2298, 2001
88. Roberts SB, Ferland G, Young VR, Morrow F, Heyman MB, Melanson KJ, Gullans SR, Dallal GE: Objective verification of dietary intake by measurement of urine osmolality. Am J Clin Nutr 54: 774-782, 1991